Literature DB >> 11689072

Exploiting subsite S1 of trypsin-like serine proteases for selectivity: potent and selective inhibitors of urokinase-type plasminogen activator.

R L Mackman1, B A Katz, J G Breitenbucher, H C Hui, E Verner, C Luong, L Liu, P A Sprengeler.   

Abstract

A nonselective inhibitor of trypsin-like serine proteases, 2-(2-hydroxybiphenyl-3-yl)-1H-indole-5-carboxamidine (1) (Verner, E.; Katz, B. A.; Spencer, J.; Allen, D.; Hataye, J.; Hruzewicz, W.; Hui, H. C.; Kolesnikov, A.; Li, Y.; Luong, C.; Martelli, A.; Radika. K.; Rai, R.; She, M.; Shrader, W.; Sprengeler, P. A.; Trapp, S.; Wang, J.; Young, W. B.; Mackman, R. L. J. Med. Chem. 2001, 44, 2753-2771) has been optimized through minor structural changes on the S1 binding group to afford remarkably selective and potent inhibitors of urokinase-type plasminogen activator (uPA). The trypsin-like serine proteases(1) that comprise drug targets can be broadly categorized into two subfamilies, those with Ser190 and those with Ala190. A single-atom modification, for example, replacement of hydrogen for chlorine at the 6-position of the 5-amidinoindole P1 group on 1, generated up to 6700-fold selectivity toward the Ser190 enzymes and against the Ala190 enzymes. The larger chlorine atom displaces a water molecule (H(2)O1(S1)) that binds near residue 190 in all the complexes of 1, and related inhibitors, in uPA, thrombin, and trypsin. The water molecule, H(2)O1(S1), in both the Ser190 or Ala190 enzymes, hydrogen bonds with the amidine N1 nitrogen of the inhibitor. When it is displaced, a reduction in affinity toward the Ala190 enzymes is observed due to the amidine N1 nitrogen of the bound inhibitor being deprived of a key hydrogen-bonding partner. In the Ser190 enzymes the affinity is maintained since the serine hydroxyl oxygen O gamma(Ser190) compensates for the displaced water molecule. High-resolution crystallography provided evidence for the displacement of the water molecule and validated the design rationale. In summation, a novel and powerful method for engineering selectivity toward Ser190 proteases and against Ala190 proteases without substantially increasing molecular weight is described.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11689072     DOI: 10.1021/jm010244+

Source DB:  PubMed          Journal:  J Med Chem        ISSN: 0022-2623            Impact factor:   7.446


  8 in total

1.  Binding affinities in the SAMPL3 trypsin and host-guest blind tests estimated with the MM/PBSA and LIE methods.

Authors:  Paulius Mikulskis; Samuel Genheden; Patrik Rydberg; Lars Sandberg; Lars Olsen; Ulf Ryde
Journal:  J Comput Aided Mol Des       Date:  2011-12-25       Impact factor: 3.686

2.  Tumor suppressor function of Liver kinase B1 (Lkb1) is linked to regulation of epithelial integrity.

Authors:  Johanna I Partanen; Topi A Tervonen; Mikko Myllynen; Essi Lind; Misa Imai; Pekka Katajisto; Gerrit J P Dijkgraaf; Panu E Kovanen; Tomi P Mäkelä; Zena Werb; Juha Klefström
Journal:  Proc Natl Acad Sci U S A       Date:  2012-01-20       Impact factor: 11.205

3.  2-Amidino analogs of glycine-amiloride conjugates: inhibitors of urokinase-type plasminogen activator.

Authors:  Archna P Massey; William R Harley; NagaRekha Pasupuleti; Fredric A Gorin; Michael H Nantz
Journal:  Bioorg Med Chem Lett       Date:  2012-01-04       Impact factor: 2.823

Review 4.  Urokinase plasminogen activator as an anti-metastasis target: inhibitor design principles, recent amiloride derivatives, and issues with human/mouse species selectivity.

Authors:  Nehad S El Salamouni; Benjamin J Buckley; Marie Ranson; Michael J Kelso; Haibo Yu
Journal:  Biophys Rev       Date:  2022-01-06

5.  Design, synthesis and biological evaluation of PSMA/hepsin-targeted heterobivalent ligands.

Authors:  Milan Subedi; Il Minn; Jianbo Chen; YunHye Kim; Kiwon Ok; Yong Woo Jung; Martin G Pomper; Youngjoo Byun
Journal:  Eur J Med Chem       Date:  2016-04-14       Impact factor: 6.514

6.  Uncharged isocoumarin-based inhibitors of urokinase-type plasminogen activator.

Authors:  Justin J Heynekamp; Lucy A Hunsaker; Thomas A Vander Jagt; Lorraine M Deck; David L Vander Jagt
Journal:  BMC Chem Biol       Date:  2006-02-08

Review 7.  Structural Principles in the Development of Cyclic Peptidic Enzyme Inhibitors.

Authors:  Peng Xu; Peter A Andreasen; Mingdong Huang
Journal:  Int J Biol Sci       Date:  2017-09-21       Impact factor: 6.580

8.  Discovery and Optimization of Indolyl-Containing 4-Hydroxy-2-Pyridone Type II DNA Topoisomerase Inhibitors Active against Multidrug Resistant Gram-negative Bacteria.

Authors:  Aleksey I Gerasyuto; Michael A Arnold; Jiashi Wang; Guangming Chen; Xiaoyan Zhang; Sean Smith; Matthew G Woll; John Baird; Nanjing Zhang; Neil G Almstead; Jana Narasimhan; Srinivasa Peddi; Melissa Dumble; Josephine Sheedy; Marla Weetall; Arthur A Branstrom; J V N Prasad; Gary M Karp
Journal:  J Med Chem       Date:  2018-05-14       Impact factor: 7.446

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.